SCHEMBL16644153

SCHEMBL16644153

Cc1nn(-c2cc(F)ccc2F)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.40
RXRA P19793 3/20 0.40
GRIN1 Q05586 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.36
RIPK1 Q13546 1/20 0.35
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ESR1 P03372 1/20 0.32
HTR7 P34969 1/20 0.32
OPRM1 P35372 1/20 0.32
ADORA1 P30542 1/20 0.31
NMT1 P30419 1/20 0.31
GLA P06280 1/20 0.31
TP53 P04637 1/20 0.30
HDAC9 Q9UKV0 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1500296 0.80 ADORA1 (0.48) RAB9AADORA1HDAC9ADORA3
SCHEMBL38651310 0.80 ADORA1 (0.48) RAB9AADORA1HDAC9ADORA3
SCHEMBL16644146 0.77 RXRA (0.33) GRIN2BRXRAGRIN1RIPK1ESR1
SCHEMBL16644138 0.71 TDO2 (0.42) GRIN2BRXRAGRIN1
SCHEMBL18277961 0.70 RXRA (0.36) GRIN2BRXRAGRIN1L3MBTL1RIPK1
SCHEMBL16202086 0.70 MEN1 (0.45) L3MBTL1NPC1RAB9AOPRM1GLA
SCHEMBL20204887 0.70 RXRA (0.48) GRIN2BRXRAGRIN1L3MBTL1NPC1
SCHEMBL3301591 0.66 CYP1A2 (0.49) L3MBTL1NPC1RAB9AESR1
SCHEMBL16090355 0.65 RAB9A (0.47) NPC1RAB9AADORA1ADORA3
SCHEMBL2359645 0.65 L3MBTL1 (0.41) GRIN2BRXRAGRIN1L3MBTL1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
WO-2015054283-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 GRIN2B 1008/4885RXRA 3701/4885GRIN1 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.